Additionally, the cardiac effects of SGLT2 inhibition may be less effective in patients with newly diagnosed dysglycemia, as observed in their study population, which primarily included individuals with IGT rather than T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.